维奈克拉联合FLAG-IDA诱导与巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果
该长期随访研究纳入138例急性髓系白血病患者(新诊断77例、复发或难治61例),采用维奈克拉联合FLAG-IDA方案治疗。新诊断队列总缓解率97%、复合完全缓解率95%、流式细胞术可检测残留病阴性率90%,3年总生存率和无事件生存率分别为66%和64%;复发或难治队列总缓解率67%、复合完全缓解率41%。
要点
- 新诊断队列总缓解率97%,复合完全缓解率95%,流式细胞术可检测残留病阴性率90%。
- 新诊断队列3年总生存率66%、无事件生存率64%,64%在首次完全缓解后接受异基因造血干细胞移植。
- 复发或难治队列总缓解率67%、复合完全缓解率41%,57%接受异基因造血干细胞移植。
核心结论
- 维奈克拉联合FLAG-IDA对新诊断及复发或难治性急性髓系白血病均能有效诱导缓解。
研究设计与样本
- 长期随访研究,纳入138例急性髓系白血病患者,其中新诊断77例、复发或难治61例,接受FLAG-IDA联合维奈克拉治疗。
- 临床试验注册号:NCT03214562。
主要发现
- 新诊断队列总缓解率97%,复合完全缓解率95%,流式细胞术可检测残留病阴性率90%,3年总生存率66%、无事件生存率64%。
- 新诊断队列各欧洲白血病网(ELN)2022风险组间结局相似,64%在首次完全缓解后接受异基因造血干细胞移植。
- 复发或难治队列总缓解率67%,复合完全缓解率41%,流式细胞术可检测残留病阴性率74%,57%接受异基因造血干细胞移植。
- 复发或难治队列中,首次挽救治疗且TP53野生型患者结局尤其有利,总缓解率79%、复合完全缓解率74%(76%可检测残留病阴性)、3年总生存率51%。
- 感染性和血液学不良事件常见,30天和60天死亡率低,与其他强化化疗方案相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax. In the ND cohort, the overall response rate (ORR) was 97%, with a composite complete remission (CRc) rate of 95% and undetectable measurable residual disease (MRD) status by flow cytometry in 90%. The 3-year OS and EFS rates were 66 and 64%, respectively. Outcomes were similar across European LeukemiaNet (ELN) 2022 risk groups. Sixty-four percent transitioned to allogeneic hematopoietic stem cell transplantation (allo-SCT) in CR1. In the RR cohort, the ORR was 67%; CRc rate 41% and flow negative MRD rate 74%; 57% transitioned to allo-SCT. The patients with RR AML in first salvage with wild-type TP53 status had particularly favorable outcomes, with an ORR of 79%, CRc rate of 74% (76% MRD undetectable) and 3-year OS rate of 51%. Infectious and hematologic adverse events were common, with low 30- and 60-day mortality similar to other intensive chemotherapy regimens. FLAG-IDA + VEN is effective for remission induction in both ND and RR AML.ClinicalTrials.gov Identifier: NCT03214562.
引用
- DiNardo CD, Jen WY, Takahashi K, et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia. 2025. PMID: 40000842. doi:10.1038/s41375-025-02531-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。